Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes.
Publication/Presentation Date
5-28-2024
Abstract
Cytoreductive therapy is not routinely recommended for younger patients with polycythemia vera (PV) due to concern that treatment toxicity may outweigh therapeutic benefits. However, no systematic data support this approach. To support objective risk/benefit assessment of cytoreductive drugs in patients with PV aged(PV
Volume
8
Issue
10
First Page
2520
Last Page
2526
ISSN
2473-9537
Published In/Presented At
Chamseddine, R. S., Savenkov, O., Rana, S., Khalid, M., Silver, R. T., Kucine, N., Scandura, J. M., & Abu-Zeinah, G. (2024). Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. Blood advances, 8(10), 2520–2526. https://doi.org/10.1182/bloodadvances.2023012459
Disciplines
Medicine and Health Sciences
PubMedID
38507746
Department(s)
Fellows and Residents
Document Type
Article
COinS